A selective glucocorticoid receptor agonist (SEGRA), sometimes called a dissociated glucocorticoid receptor agonist (DIGRA), is a type of experimental drug that is designed to share many of the desirable anti-inflammatory and immunosuppressive properties of classical glucocorticoid drugs but with fewer side effects such as skin atrophy. As of November 2010, Phase II clinical trials with the SEGRA mapracorat investigating the topical treatment of atopic dermatitis and inflammation following cataract surgery have been completed, but no results are available. Such trials attempt to determine whether the theoretical concept translates into an actual clinical benefit.
Read more about Selective Glucocorticoid Receptor Agonist: History, Mechanism of Action, Potential Applications, Chemistry, See Also
Famous quotes containing the words selective and/or receptor:
“The selective memory isn’t selective enough.”
—Blake Morrison (b. 1950)
“The disinterest [of my two great-aunts] in anything that had to do with high society was such that their sense of hearing ... put to rest its receptor organs and allowed them to suffer the true beginnings of atrophy.”
—Marcel Proust (1871–1922)